Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

M. S. Wen, M. T.M. Lee, J. J. Chen, H. P. Chuang, L. S. Lu, C. H. Chen, T. H. Lee, C. T. Kuo, F. M. Sun, Y. J. Chang, P. L. Kuan, Y. F. Chen, M. J. Charng, C. Y. Ray, J. Y. Wu, Y. T. Chen*

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

146 引文 斯高帕斯(Scopus)

摘要

Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose. We conducted a prospective study in which warfarin dose was prescribed based on CYP2C9 and VKORC1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic international normalized ratio (INR) within 2 weeks of treatment initiation and none of the patients developed clinical bleeding or thromboembolic event. Ten percent (11) of patients with INR >4 and no clinical bleeding were detected during this study. At 12 weeks, 69% of the patients' maintenance doses matched the prediction. Dosing algorithms incorporating genetic factors, age, and body surface area were developed, which could explain up to 62% of the total variation (R2 of 0.62). This study demonstrated that pharmacogenetics-based dosing could improve time to stable, therapeutic INR, reduce adverse events, and achieve high sensitivity.

原文英語
頁(從 - 到)83-89
頁數7
期刊Clinical Pharmacology and Therapeutics
84
發行號1
DOIs
出版狀態已出版 - 07 2008

指紋

深入研究「Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes」主題。共同形成了獨特的指紋。

引用此